Nuvation Bio Inc. Class A Common Stock vs Consumer Staples Select Sector SPDR Fund — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Consumer Staples Select Sector SPDR Fund trades at $83.05 (market cap $13.44B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 7.9× Nuvation Bio Inc. Class A Common Stock's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| NUVB | XLP | |
|---|---|---|
Market Cap | $1.71B | $13.44B |
Volume | 5,448,712 | 9,437,177 |
Sector | Health | — |
52-Week High | $9.54 | $90.00 |
52-Week Low | $3.41 | $75.61 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $1.30B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLP trades at $81.70, down 0.09% with a bearish technical outlook as moving averages signal selling pressure. The ETF shows strong analyst support with a 100% buy rating from 2 analysts. Recent news highlights XLP's 6.6% YTD gain outperforming discretionary peers, though it faces headwinds from rising interest rates pressuring dividend stocks.
XLP offers defensive exposure to consumer staples with a low 0.08% expense ratio and upcoming dividend. Key risks include persistent inflation and interest rate sensitivity, but the fund's quality holdings provide stability during market volatility. The technical setup suggests near-term consolidation around current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →